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Abstract Melanoma growth, angiogenesis and metastatic
progression are strongly promoted by the inflammatory
tumor microenvironment due to high levels of cytokine
and chemokine secretion by the recruited inflammatory and
stromal cells. In addition, platelets and molecular compo-
nents of procoagulant pathways have been recently emerg-
ing as critical players of tumor growth and metastasis. In
particular, thrombin, through the activity of its receptor
protease-activated receptor-1 (PAR-1), regulates tumor cell
adhesion to platelets and endothelial cells, stimulates tumor
angiogenesis, and promotes tumor growth and metastasis.
Notably, in many tumor types including melanoma, PAR-1
expression directly correlates with their metastatic phenotype
and is directly responsible for the expression of interleukin-8,
matrix metalloproteinase-2 (MMP-2), vascular endothelial
growth factor, platelet-derived growth factor, and integrins.
Another proinflammatory receptor–ligand pair, platelet-
activating factor (PAF) and its receptor (PAFR), have been
shown to act as important modulators of tumor cell adhe-
sion to endothelial cells, angiogenesis, tumor growth and
metastasis. PAF is a bioactive lipid produced by a variety
of cells from membrane glycerophospholipids in the same
reaction that releases arachidonic acid, and can be secreted
by platelets, inflammatory cells, keratinocytes and endothe-
lial cells. We have demonstrated that in metastatic mela-
noma cells, PAF stimulates the phosphorylation of cyclic
adenosine monophosphate response element-binding protein
(CREB) and activating transcription factor 1 (ATF-1), which
results in overexpression of MMP-2 and membrane type 1-
MMP (membrane type 1-MMP). Since only metastatic
melanoma cells overexpress CREB/ATF-1, we propose that
metastatic melanoma cells are better equipped than their non-
metastatic counterparts to respond to PAF within the tumor
microenvironment. The evidence supporting the hypothesis
that the two G-protein coupled receptors, PAR-1 and PAFR,
contribute to the acquisition of the metastatic phenotype of
melanoma is presented and discussed.
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VEGF vascular endothelial growth factor
PDGF platelet-derived growth factor
PAF platelet-activating factor
PAFR PAF receptor
CREB cyclic AMP-response element-binding
protein
ATF-1 activating transcription factor-1
ECM extracellular matrix
bFGF basic fibroblast growth factor
uPA urokinase-type plasminogen activator
TNF-α tumor necrosis factor-α
GM-CSF granulocyte-macrophage colony-
stimulating factor
TGF-β transforming growth factor-β
IGF-1 insulin-like growth factor-1
HGS/SF hepatocyte growth factor/scatter factor
GRO-α growth related oncogene-α
NK cells natural killer cells
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STAT signal transducer and activator of transcription
PKA protein kinase A
Introduction
The development of tumor metastasis is a complex cascade
of events [1]. Potentially, metastatic cells have to exit the
primary tumor site by loosening cell to cell contact, adher-
ing to and degrading extracellular matrix (ECM), migrating
through the subendothelial basement membrane of local
post-capillary veins and lymphatic vessels and intravasat-
ing. Once in circulation, tumor cells face severe mechanical
and immunosurveillance challenges. Surviving cells can
arrest in the peripheral capillary bed of a distant organ,
adhere to the subendothelial basement membrane, extrav-
asate, adhere and migrate through the ECM, and form a
colony at the new metastatic site. Further induction of neo-
angiogenesis must occur to assure continuous growth [1].
An expending amount of data reveals the importance of
an inflammatory microenvironment and stroma in cancer
initiation and progression, which brings new directions and
approaches to cancer treatment [2–8]. Genetic and func-
tional experiments indicated that inflammatory cells such as
tumor-infiltrating monocytes/macrophages, neutrophils,
mast cells, eosinophils and activated T and B lymphocytes,
as well as stromal fibroblasts contribute to malignancies by
releasing growth and survival factors, as well as extracel-
lular proteases, and other proangiogenic factors [2–7].
Melanoma, as with all other cancers, is comprised of a
group of heterogeneous cells that co-exist and interact with
an infrastructure of other cells (keratinocytes, fibroblasts,
endothelial cells, inflammatory cells) and extracellular matrix
components (laminin, collagen), growth factors (vascular
endothelial growth factor (VEGF), basic fibroblast growth
factor (bFGF), thrombin), as well as proteases and interleu-
kins involved in invasion (matrix metalloproteinases (MMPs),
interleukin-8 (IL-8), urokinase-type plasminogen activator)
[9–11]. As described by Haass and Herlyn [9], alterations in
keratinocyte-mediated contact growth inhibition in the skin
may drive the malignant transformation of melanocytes.
Keratinocytes that are activated by ultraviolet (UV) for
example, release interleukins 1, 3, 6 and 8, secrete tumor
necrosis factor-α (TNF-α), granulocyte-macrophage colony-
stimulating factor, and generate the proinflammatory biolipid
platelet-activating factor (PAF), contributing to melanoma
development and progression [12–16]. Within the tumor
microenvironment, a rapid proliferation of fibroblasts, whose
role has been neglected previously, is supported by platelet-
derived growth factor (PDGF), bFGF and transforming
growth factor-β (TGF-β) produced by melanoma as well
as inflammatory cells [10, 17]. In turn, fibroblasts produce a
series of growth factors such as insulin-like growth factor-1,
hepatocyte growth factor (HGF)/scatter factor, bFGF, and
TGF-β that further support the growth and proliferation
of melanoma cells [10, 17]. Recently, fibroblasts have been
shown to remodel the matrix and form “tracks” creating a
leading edge for tumor cells invasion [18]. Strong associa-
tion has been shown between the recruitment of Tie-2 (an
angiopoietin receptor)-expressing monocytes and tumor
angiogenesis, and between MMP-9-secreting tumor asso-
ciated macrophages and tumor cell invasion [18–21]. In
addition, platelets and molecular components of the coagu-
lation system and platelet activation pathways have been
emerging as critical players of tumor growth and metastasis
[22–24]. Overall, it is now believed that cancer cells initiate
a pathological cycle, whereby through the constitutive
activity of major inflammatory signaling pathways such as
nuclear factor-κB (NF-κB), signal transducer and activator
of transcription 3 (STAT3) and cyclooxygenases-2 (COX-2)-
driven lipid metabolism, they trigger the recruitment and
activation of the inflammatory cells, stroma and platelets [3–
5, 25–29]. In turn, cells within the tumor microenvironment
produce inflammatory mediators and angiogenic factors or
adhesion-stimulating factors to further amplify the metastatic
phenotype [3–5, 25–29].
The progression of melanoma from radial growth phase
to vertical growth phase and metastatic dissemination are
accompanied by multiple molecular changes [30]. This
review will focus on the role of molecular intermediates of
the coagulation and platelet activation pathways in tumor
metastasis. Specifically, we will focus on the thrombin
receptor protease-activated receptor (PAR-1) and the plate-
let-activating factor receptor (PAFR). We will provide
evidence for sensitization of metastatic melanoma cells to
the stimulatory effects of thrombin and PAF.
Role of Coagulation and Platelet Activation
in Tumor Growth and Metastasis
Tumor cells produce and activate the components of the
coagulation/platelet activation pathways—thrombin, tissue
factor, fibrinogen, von Willebrand factor (VWF) and PAF
[23, 31, 32]. Thrombin is an essential component of the
tumor microenvironment already present at the primary
tumor site because of the leaky nature of the tumor vascu-
lature. There, the migration of tumor cells into the vascu-
lature is stimulated by thrombin, which is induced by tissue
factor on the surface of most tumor cells [23].
Tumor–host cell interaction becomes vital for the survival
of potentially metastatic cells during vascular dissemination.
In the circulation, thrombin and other tumor-secreted agents
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activate endothelial cells to express P-selectin on their
surface. P-selectin binds weakly to tumor cells containing
the P-selectin ligand receptor. Weakly activated platelets also
bind tumor cells via P-selectins. This induces weak tethering
of tumor to the endothelium and platelets [23, 31–34]. A
tighter combination of platelets and tumor cells develops,
which produces thrombin at a more rapid rate, since plate-
lets provide a catalytic surface for thrombin generation
from coagulant proteins. This leads to a firm bond between
platelets and tumor cells, mediated by platelet integrin IIb–
IIIa binding to tumor integrins via VWF, fibronectin, and
other RGDS-domain containing ligands [23]. Platelet acti-
vation also leads to angiogenesis via thrombin-stimulated
synthesis and secretion of VEGF and growth related
oncogene-α from tumor cells, as well as release of PDGF,
VEGF, and angiopoietin-1 from platelets, and increased
angiopoietin-2 and kinase insert-domain-containing receptor
in endothelial cells [35–37]. In addition, stimulated platelets
are an important source of growth and angiogenesis-
inducing biolipids lysophosphatidic acid and PAF [38].
Besides mediating adhesion to endothelial cells and develop-
ment of collateral vessels, platelet-tumor aggregates protect
tumor cells from natural killer cells [39]. These aggregates
further embolize, leading to ischemia and endothelial cell
denudation [23]. As a result, tumor cells and platelets bind
more avidly to the subendothelial basement membrane and
matrix. Finally, tumor emboli lead to tumor extravasation
into the parenchyma and neoangiogenesis [23].
Thrombin is also a prominent angiogenic factor. It pro-
motes endothelial cell alignment in Matrigel in vitro and
angiogenesis in vivo [40]. It induces the differentiation of
endothelial cells into capillary structures on Matrigel and
increases endothelial cell migration [40].
The Role of PAR-1 in Tumor Growth and Metastasis
Thrombin not only stimulates platelets and induces angio-
genesis, it also directly activates tumor cells through the
activity of its receptor PAR-1. The thrombin receptor is a
seven transmembrane-spanning G-protein coupled receptor.
Unlike typical ligand receptor interactions, thrombin does
not activate PAR-1 upon binding. Rather, it cleaves the N-
terminus of PAR-1 at serine 42. Upon cleavage, the new
amino terminal peptide acts as a tethered ligand that will
now bind to the body of the receptor thereby causing cell
signaling via G-proteins. As mentioned above, in order to
activate thrombin, melanoma and other tumor cells con-
stitutively express tissue factor (TF) [31, 32]. The hypoxic
tumor microenvironment also induces TF expression by
endothelial cells, tumor associated macrophages and myo-
fibroblasts thereby also augmenting thrombin production in
the tumor microenvironment [41]. PAR-1 can also be acti-
vated by ligands other than thrombin such as factor Xa,
granzyme A, trypsin and plasmin [33, 42, 43]. It has also
been reported recently that PAR-1 in breast cancer cells can
be proteolytically cleaved and activated by MMP-1 [44].
In tumor cells, PAR-1 stimulates expression of adhesion
molecules such as integrins αIIbβ3, αvβ5, and αvβ3 [45–
47]. Indeed, thrombin-treated melanoma cells enhance
their adhesion to platelets and fibronectin in vitro [48]. In
various types of cells, including vascular endothelial cells,
PAR-1 activation results in upregulation of gene products
involved in invasion (MMP-2) [49], and angiogenesis (IL-
8, VEGF, bFGF, PDGF) [50–53]. In human melanoma
cells, thrombin acts as a growth factor and is mitogenic
[32]. Overall, thrombin and PAR-1 contribute to the
acquisition of the metastatic phenotype of melanoma by
facilitating tumor invasion and metastasis through the
induction of cell adhesion molecules, matrix degrading
proteases, and stimulating the secretion of angiogenic fac-
tors into the melanoma tumor microenvironment (Fig. 1).
Our tissue analysis from patients demonstrated that PAR-
1 is overexpressed predominantly in malignant melanoma
tumors and in metastatic lesions as compared to common
melanocytic nevi and normal skin [54]. Furthermore, a
significantly higher percentage of PAR-1 positive cells was
found in metastatic melanoma specimens as compared to
both dysplastic nevi and primary melanoma specimens
[55]. In addition to melanoma, overexpression of PAR-1
has been observed in a variety of human cancers such as
breast, lung, colon, pancreatic and prostate [44, 56–59]. We
further demonstrated that PAR-1 is overexpressed in highly
metastatic melanoma cell lines as compared to non-
Fig. 1 Schematic representation of molecules involved in cell
invasion and angiogenesis via activation of PAR-1 which is
overexpressed in metastatic melanoma cells. Thrombin from the
microenvironment cleaves the N-terminus of PAR-1 to activate the
receptor. The tumor-promoting signals transduced by PAR-1 through G-
proteins upregulate molecules involved in angiogenesis and invasion
PAR-1 and PAF in melanoma 105
metastatic ones [34, 60]. We found that the overexpression of
PAR-1 in the highly invasive and aggressive melanoma cell
lines correlates with the loss of the activator protein-2α (AP-
2α) transcription factor, which is a crucial event in the
progression of human melanoma [60]. An inverse correlation
between AP-2α and PAR-1 expression was also established
using a “progressive” melanoma tissue microarray [55].
The Role of PAFR in Melanoma Progression
Activated platelets release another proangiogenic biolipid-
platelet-activating factor. PAF is a potent proinflammatory
mediator and the first bioactive lipid ever identified [61–64].
PAF may be produced from the 1-O-alkyl-2-arachidonoyl-
sn-glycero-3-phosphocholine via enzymatic hydrolysis cata-
lyzed by phospholipase A2 [65–69]. In a parallel process, the
arachidonic acid released in the first reaction is further
converted by the COX-2 enzyme to form the precursor of
prostanoids. PAF acts through the specific seven transmem-
brane-spanning G-protein-coupled receptor PAFR [70–72].
Studies on inflammatory cells, endothelial cells, keratino-
cytes, and various other types of cells demonstrated that a
long lasting consequence of transient stimulation with highly
unstable PAF and PAF-like biolipids is the expression of
inflammatory cytokines and mediators such as IL-6, IL-8,
IL-10, COX-2, VEGF and inducible nitric oxide synthase
(Table 1) [24–26]. An essential role of PAF as a second
messenger in endothelial and inflammatory cells was further
established following the findings that lipopolysaccharide-,
IL-1- and TNF-α- induced activation of NF-κB is a PAF-
dependent process [27].
PAF and Angiogenesis
PAF is a potent mediator of tumor neoangiogenesis [73–
79]. Numerous reports showed that PAF can activate
endothelial cells directly, as well as mediate angiogenesis
induced by other angiogenic factors [74, 80]. Camussi’s
group demonstrated that PAF produced by breast or
Kaposi’s sarcoma cancer cells induces and sustains the in
vivo neoangiogenesis in experimental tumor models [80,
81]. Robert and Hunt [79] has demonstrated the effective-
ness of PAF antagonists in the inhibition of angiogenesis in
prostate cancer xenografts. The same group showed that
PAF induces activation of matrix metalloproteinase-2
activity and vascular endothelial cell invasion and migra-
tion [82]. They further found that bFGF stimulated PAF-
dependent proliferation in human umbilical vein endothelial
cells (HUVEC) [83]. HGF and TNF-α both induce angio-
genesis through mechanisms that involve the production of
PAF [75, 77, 78]. Montrucchio et al. [77] demonstrated that
nitric oxide mediates the angiogenesis induced by PAF or
TNF, the latter itself being dependent on the production of
PAF. Brizzi et al. [73] showed that HUVECs express the
thrombopoietin receptor, which activates cell migration in
Table 1 Role of PAF in the biology of various cells
Cell type Function
Platelets Secrete PAF upon activation with thrombin
PAF induces aggregation and secretion of serotonin and histamine
Neutrophils Secrete PAF upon activation
PAF induces chemotaxis, production of ROS and TNF-a and
rolling and adhesion on endothelial cells
Macrophages Secrete PAF upon activation
PAF primes tissue-fixed macrophages for activation with inflammatory mediators
PAF induces production of angiogenic factors VEGF, bFGF, TNFα and IL-1β
Endothelial cells Produce PAF
PAF mediates bFGF-induced proliferation via Src-JAK2-STAT3 pathway
PAF induces migration and formation of focal adhesions via activation of Src kinase, STAT-3 and FAK
PAF induces production of TNFα and IL-1α, bFGF, VEGF and COX-2
Keratinocytes Secrete PAF and PAF-like substances upon irradiation with UV
PAF induces expression of COX-2, IL-6 and IL-8
Fibroblasts PAF induces proliferation
Platelets, inflammatory cells, vascular endothelial cells, keratinocytes and fibroblasts produce PAF and respond to PAF. In response to thrombin,
platelets secrete the pre-stored PAF. In neutrophils, PAF mediates chemotaxis, rolling and adhesion on endothelial cells, and production of reactive
oxygen species and TNF-α. In macrophages, it mediates production of angiogenic factors. In endothelial cells, PAF can directly induce or be a
second messenger in growth factor- or cytokine-induced proliferation and migration. PAF also mediates the production of TNF-α, IL-1α, bFGF,
VEGF and COX-2 in endothelial cells. Keratinocytes produce PAF when irradiated with UV, and respond to PAF by induction of COX-2, IL-6
and IL-8. PAF further mediates the proliferation in fibroblasts
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vitro and angiogenesis in vivo; these effects were mediated
by PAF- and IL-8-dependent phosphorylation of STAT1
and STAT5B. Furthermore, it was found that vascular
permeability induced by VEGF was mediated by PAF [84].
In HUVECs, both VEGF-induced P-selectin translocation
and subsequent neutrophil adhesion requires PAF synthesis
[85]. Moreover, angiopoietin-1, and -2 stimulate PAF
synthesis [86].
PAF and PAF Receptor in Melanoma
The first demonstration of the role of PAF in melanoma
metastasis was made in 1996 by Im et al. [87]. They found
that IL-1α and TNF-α-induced increase in experimental
pulmonary metastasis produced by the B16F10 murine
melanoma cells in C57Bl/6 mice was augmented by a
single intraperitoneal injection of PAF [87]. Several
repeated injections of PAFR antagonist BN50739 (day 0
through 2) decreased both IL-1α and TNF-α-induced
metastasis as well as control lung metastasis, suggesting
the role of endogenous PAF in tumor cell lung colonization.
PAF caused an increase in the retention of radiolabeled
B16F10 cells in the lungs, suggesting that stimulation of
endothelial cell adhesion was the primary mechanism for
the observed pro-metastatic effect of PAF [87].
PAFR transgenic mice exhibited progressive hyperproli-
ferative changes in the epidermis as soon as 2 weeks after
birth. The keratinocyte hyperplasia was accompanied by
hyperpigmentation and an increase in the number of dermal
melanocytes in the ear and tail, with consequent develop-
ment of melanocytic tumors late in life [88, 89]. The PAFR
transgene expression was detected in keratinocytes but not
in melanocytes, suggesting that the progressive recruitment
of melanocytes to the dermis was driven by keratinocytes,
and possibly by the accumulating fibroblasts and mast cells.
In human skin, all these types of cells are indeed known to
play a significant role in regulating skin homeostasis and
behavior of resident melanocytes, as well as melanoma
growth and local malignant invasion [10].
In human skin, the melanocyte homeostasis and number
is tightly controlled by neighboring keratinocytes through
an E-cadherin-mediated adhesion [10]. Essential for mela-
noma tumorigenesis, keratinocytes and corneal stromal
cells secrete PAF in response to UV exposure [13, 14, 90–
92]. Keratinocytes express PAF receptors on their surface
[93], and PAF upregulates their COX-2, IL-6, and IL-
8 mRNA expression and prostaglandin E2 secretion [14,
15]. Although the incidence of severe sunburns in child-
hood have been linked to melanoma development later in
life, the precise mechanism by which UV contributes to
melanomagenesis has not been discovered. This mechanism
may involve, at least in part, UV-induced immunosuppres-
sion [94, 95]. Interestingly, Walterscheid et al. [15] have
found that the UVB-induced inflammation in mouse skin
and the consequent systemic immunosuppression was
abolished by PAFR antagonists. Indeed, Travers’s group
has demonstrated UVB-induced generation of PAF-like sub-
stances in human epidermal keratinocytes [13]. Furthermore,
staphylococcal lipoteichoic acid was also found to inhibit
the delayed-type hypersensitivity reactions via direct bind-
ing to the platelet-activating factor receptor [96]. It is
therefore possible that PAF and other PAFR agonists are
not only important for melanoma cell biology, but that they
may play a pivotal role in tumor growth by ‘negatively’
modulating the immune system and inhibiting Th1 cyto-
toxic responses.
Further support for the role of PAF receptor in melanoma
growth and metastatic dissemination came from the
experimental systems utilizing in vitro and in vivo murine
melanoma models. Indeed, it was reported that inhibition
of PAF activity by means of overexpressing PAF-acetyl-
hydrolase in B16F10 murine melanoma cells led to a sig-
Fig. 2 A model for the stimulation of MMP-2 and MT1-MMP by
PAF via activation of CREB/ATF-1. We propose that melanoma cells,
regardless of their metastatic potential, express PAFR and secrete
basal levels of MMP-2 and MT1-MMP. However, within the
melanoma tumor microenvironment, melanoma cells come into
contact with platelets, endothelial cells, and inflammatory cells that
secrete PAF. PAF, through the activity of its receptor on tumor cells
and a signaling cascade involving pertussis-toxin-insensitive Gαq
protein, adenylate cyclase, p38 MAPK and PKA, phosphorylates
CREB and ATF-1. Activation of this and possibly other signaling
mechanisms results in overexpression and secretion of MMP-2 and
MT1-MMP. However, since only metastatic melanoma cells over-
express CREB and ATF-1, they are better equipped to respond to the
stimulatory effect of PAF within the tumor microenvironment
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nificant decrease in tumor vascularization and growth,
allowing longer animal survival [97]. Most recently, Fallani
et al. have demonstrated that PAF is being synthesized by
B16F10 cells in response to interferon-γ treatment, and that
PAF promoted the invasion of these cells through the
Matrigel-coated filters [98]. Moreover, it has been shown
that a single intraperitoneal injection of PAF induced
expression of MMP-9 and MMP-2 in the mouse lungs,
and significantly enhanced B16F10 pulmonary lung metas-
tasis, suggesting an additional, non-tumor-cell mechanism
of PAF action [99]. Authors further showed that selective
inhibition of MMP-9, which was expressed by bronchial
epithelial cells as well as in the walls of blood vessels after
stimulation with PAF, completely prevented B16F10 metas-
tasis, whereas selective inhibition of MMP-2 was insuffi-
cient [99]. Notably, MMP-9 is expressed predominantly by
tumor stroma, where it is believed to play a critical role in
tumor invasion and extracellular growth factor activation.
Indeed, in mouse models of squamous carcinogenesis,
MMP- 9 was predominantly found in neutrophils, macro-
phages, and mast cells, rather than in oncogene-positive
neoplastic cells [21]. In the human melanoma cell line
Hs294T, PAFR antagonists were able to prevent adhesion to
IL-1-stimulated endothelial cells [100].
Our in vivo experiments showed that the PAF receptor
antagonist PCA4248 acts as a potent inhibitor of experi-
mental melanoma human lung metastasis when delivered
intravenously before melanoma cell inoculation. Further-
more, daily treatments with PCA4248 inhibited growth of
established microscopic tumor cell colonies in the lungs.
This indicates that antagonizing PAFR activity could serve
as a point of intervention during vascular dissemination or
tumor/metastasis outgrowth [101].
PAF Induces MMP-2 and MT1-MMP in Melanoma
in part via Activation of CREB/ATF-1
Recently, we have examined the role of PAF in human
melanoma metastasis and found that PAF receptor was
expressed in all cultured melanoma cell lines regardless of
their metastatic potential [101]. In metastatic melanoma cell
lines, which are known to overexpress cyclic adenosine
monophosphate (cAMP)-response element-binding protein
(CREB) and activating transcription factor-1 (ATF-1) tran-
scription factors, PAF induced CREB and ATF-1 phos-
phorylation as well as secretion and activation of MMP-2
and membrane type 1 (MT1)-MMP via a PAFR-mediated
signal transduction mechanism that required pertussis
toxin-insensitive Gαq protein and adenylate cyclase activity
and was antagonized by a cAMP-dependent protein kinase
A (PKA) and p38 mitogen activated protein kinase
(MAPK) inhibitors [101]. Other kinases and transcription
factors may be also involved in PAF-induced activation of
MMP-2, such as janus kinase-2-Src-STAT-3 regulatory
node, as demonstrated in HUVEC cells [83, 102]. We
propose that all melanoma cells, regardless of their
metastatic potential, express PAFR and secrete basal levels
of MMP-2 and MT1-MMP. However, within the melanoma
tumor microenvironment, where melanoma cells come into
contact with PAF-secreting cells such as platelets, endothe-
lial cells, and inflammatory cells, PAF will phosphorylate
CREB and ATF-1 through the activity of its receptor and a
signaling cascade involving p38 MAPK and PKA. This
mechanism, as well as other possible regulatory pathways
will further result in overexpression and secretion of MMP-
2 and MT1-MMP (Fig. 2). However, since only metastatic
melanoma cells overexpress CREB and ATF-1, they are,
therefore, better equipped to respond to the effect of PAF
within the tumor microenvironment.
Conclusion
It is apparent that interactions between tumor cells and
the components of the coagulation and platelet activation
pathways is critical for tumor growth and metastatic
dissemination. Through the activity of their specific
receptors on various types of cells including platelets,
endothelial and tumor cells, thrombin and platelet-activating
factor promote inflammatory and angiogenic responses,
the remodeling of the extracellular matrix as well as the
process of vascular dissemination. PAR-1 is overexpressed
in metastatic melanoma cells. Its activation by thrombin
promotes secretion of adhesion, angiogenic and survival
factors into the tumor microenvironment allowing for
increased metastatic potential of melanoma. Simultaneously,
many inflammatory stimuli can trigger production of PAF
by an array of cells, including tumor cells. Activated PAFR
causes stimulation of the CREB and ATF-1 transcription
factors in melanoma, which in turn increase the secretion of
MMP-2 and MT1-MMP. Since metastatic melanoma cells
overexpress PAR-1 as well as CREB/ATF-1 downstream of
PAFR signaling pathway, we speculate that metastatic
melanoma cells are better equipped to respond to inflamma-
tory stimulation from the tumor microenvironment.
References
1. Fidler IJ (2003) The pathogenesis of cancer metastasis: the ‘seed
and soil’ hypothesis revisited. Nat Rev Cancer 3(6):453–458
2. Balkwill F, Mantovani A (2001) Inflammation and cancer: back
to Virchow. Lancet 357(9255):539–545
3. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature
420(6917):860–867
4. Mantovani A (2005) Cancer: inflammation by remote control.
Nature 435(7043):752–753
108 V.O. Melnikova, et al.
5. Pikarsky E et al (2004) NF-kappa B functions as a tumour
promoter in inflammation-associated cancer. Nature 431
(7007):461–466
6. Smalley KS, Lioni M, Herlyn M (2005) Targeting the stromal
fibroblasts: a novel approach to melanoma therapy. Expert Rev
Anticancer Ther 5(6):1069–1078
7. Denardo DG, Johansson M, Coussens LM (2007) Immune cells
as mediators of solid tumor metastasis. Cancer Metastasis Rev
DOI 10.1007/s10555-007-9100-0
8. Tlsty TD, Coussens LM (2006) Tumor stroma and regulation of
cancer development. Annu Rev Pathol 1:119–150
9. Haass NK, Herlyn M (2005) Normal human melanocyte
homeostasis as a paradigm for understanding melanoma. J
Investig Dermatol Symp Proc 10(2):153–163
10. Lee JT, Herlyn M (2006) Microenvironmental influences in
melanoma progression. J Cell Biochem 101(4):862–872
11. Postovit LM et al (2006) Influence of the microenvironment on
melanoma cell fate determination and phenotype. Cancer Res 66
(16):7833–7836
12. Schwarz T, Luger TA (1989) Effect of UV irradiation on epidermal
cell cytokine production. J Photochem Photobiol B 4(1):1–13
13. Marathe GK et al (2005) Ultraviolet B radiation generates platelet-
activating factor-like phospholipids underlying cutaneous damage.
J Biol Chem 280(42):35448–35457
14. Pei Y et al (1998) Activation of the epidermal platelet-activating
factor receptor results in cytokine and cyclooxygenase-2 biosynthesis.
J Immunol 161(4):1954–1961
15. Walterscheid JP, llrich SE, Nghiem DX (2002) Platelet-activating
factor, a molecular sensor for cellular damage, activates systemic
immune suppression. J Exp Med 195(2):171–179
16. Ullrich SE (2005) Mechanisms underlying UV-induced immune
suppression. Mutat Res 571(1–2):185–205
17. Hsu MY, Meier F, Herlyn M (2002) Melanoma development and
progression: a conspiracy between tumor and host. Differentiation
70(9–10):522–536
18. Gaggioli C et al (2007) Fibroblast-led collective invasion of
carcinoma cells with differing roles for RhoGTPases in leading
and following cells. Nat Cell Biol 9(12):1392–1400
19. De Palma M et al (2005) Tie2 identifies a hematopoietic lineage
of proangiogenic monocytes required for tumor vessel formation
and a mesenchymal population of pericyte progenitors. Cancer
Cell 8(3):211–226
20. Lewis CE, De Palma M, Naldini L (2007) Tie2-expressing
monocytes and tumor angiogenesis: regulation by hypoxia and
angiopoietin-2. Cancer Res 67(18):8429–8432
21. Coussens LM et al (2000) MMP-9 supplied by bone marrow-
derived cells contributes to skin carcinogenesis. Cell 103
(3):481–490
22. Gasic GJ, Gasic TB, Stewart CC (1968) Antimetastatic effects
associated with platelet reduction. Proc Natl Acad Sci U S A 61
(1):46–52
23. Nierodzik ML, Karpatkin S (2006) Thrombin induces tumor
growth, metastasis, and angiogenesis: evidence for a thrombin-
regulated dormant tumor phenotype. Cancer Cell 10(5):355–362
24. Nierodzik ML et al (1998) Protease-activated receptor 1 (PAR-1)
is required and rate-limiting for thrombin-enhanced experimental
pulmonary metastasis. Blood 92(10):3694–3700
25. Gupta RA, Dubois RN (2001) Colorectal cancer prevention and
treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1
(1):11–21
26. Affara NI, Coussens LM (2007) IKK alpha at the crossroads of
inflammation and metastasis. Cell 129(1):25–26
27. Brown JR, DuBois RN (2004) Cyclooxygenase as a target in
lung cancer. Clin Cancer Res 10(12 Pt 2):4266s–4269s
28. Dauer DJ et al (2005) Stat3 regulates genes common to both
wound healing and cancer. Oncogene 24(21):3397–3408
29. Robinson SC, Coussens LM (2005) Soluble mediators of
inflammation during tumor development. Adv Cancer Res
93:159–187
30. Nyormoi O, Bar-Eli M (2003) Transcriptional regulation of
metastasis-related genes in human melanoma. Clin Exp Metastasis
20(3):251–263
31. Bromberg ME et al (1995) Tissue factor promotes melanoma
metastasis by a pathway independent of blood coagulation. Proc
Natl Acad Sci U S A 92(18):8205–8209
32. Fischer EG, Ruf W, Mueller BM (1995) Tissue factor-initiated
thrombin generation activates the signaling thrombin receptor on
malignant melanoma cells. Cancer Res 55(8):1629–1632
33. Ruf W, Mueller BM (2006) Thrombin generation and the
pathogenesis of cancer. Semin Thromb Hemost 32(Suppl
1):61–68
34. Tellez C, Bar-Eli M (2003) Role and regulation of the thrombin
receptor (PAR-1) in human melanoma. Oncogene 22(20):3130–
3137
35. Kepner N, Lipton A (1981) A mitogenic factor for transformed
fibroblasts from human platelets. Cancer Res 41(2):430–432
36. Mohle R et al (1997) Constitutive production and thrombin-
induced release of vascular endothelial growth factor by human
megakaryocytes and platelets. Proc Natl Acad Sci U S A 94
(2):663–668
37. Li JJ et al (2001) Thrombin induces the release of angiopoietin-1
from platelets. Thromb Haemost 85(2):204–206
38. Boucharaba A et al (2004) Platelet-derived lysophosphatidic acid
supports the progression of osteolytic bone metastases in breast
cancer. J Clin Invest 114(12):1714–1725
39. Nieswandt B et al (1999) Lysis of tumor cells by natural killer
cells in mice is impeded by platelets. Cancer Res 59(6):1295–
1300
40. Haralabopoulos GC et al (1997) Thrombin promotes endothelial
cell alignment in Matrigel in vitro and angiogenesis in vivo. Am
J Physiol 273(1 Pt 1):C239–C245
41. Ruf W (2007) Tissue factor and PAR signaling in tumor
progression. Thromb Res 120(Suppl 2):S7–S12
42. Hansen KK, Saifeddine M, Hollenberg MD (2004) Tethered
ligand-derived peptides of proteinase-activated receptor 3
(PAR3) activate PAR1 and PAR2 in Jurkat T cells. Immunology
112(2):183–190
43. O'Brien PJ et al (2001) Protease activated receptors: theme and
variations. Oncogene 20(13):1570–1581
44. Boire A et al (2005) PAR1 is a matrix metalloprotease-1 receptor
that promotes invasion and tumorigenesis of breast cancer cells.
Cell 120(3):303–313
45. Even-Ram SC et al (2001) Tumor cell invasion is promoted by
activation of protease activated receptor-1 in cooperation with
the alpha v beta 5 integrin. J Biol Chem 276(14):10952–10962
46. Wojtukiewicz MZ et al (1992) Thrombin enhances tumor cell
adhesive and metastatic properties via increased alpha IIb beta 3
expression on the cell surface. Thromb Res 68(3):233–245
47. Senger DR et al (1996) Stimulation of endothelial cell migration
by vascular permeability factor/vascular endothelial growth factor
through cooperative mechanisms involving the alphavbeta3
integrin, osteopontin, and thrombin. Am J Pathol 149(1):293–305
48. Nierodzik ML et al (1996) Presence of the seven transmembrane
thrombin receptor on human tumour cells: effect of activation on
tumour adhesion to platelets and tumor tyrosine phosphorylation.
Br J Haematol 92(2):452–457
49. Zucker S et al (1995) Thrombin induces the activation of
progelatinase A in vascular endothelial cells. Physiologic
regulation of angiogenesis. J Biol Chem 270(40):23730–23738
50. Shimizu S et al (2000) Thrombin stimulates the expression of
PDGF in lung epithelial cells. Am J Physiol Lung Cell Mol
Physiol 279(3):L503–L510
PAR-1 and PAF in melanoma 109
51. Ueno A et al (1996) Thrombin stimulates production of interleukin-
8 in human umbilical vein endothelial cells. Immunology 88(1):76–
81
52. Cucina A et al (1999) Thrombin induces production of growth
factors from aortic smooth muscle cells. J Surg Res 82(1):61–66
53. Huang YQ et al (2001) Thrombin induces increased expression
and secretion of VEGF from human FS4 fibroblasts, DU145
prostate cells and CHRF megakaryocytes. Thromb Haemost 86
(4):1094–1098
54. Massi D et al (2005) Expression of protease-activated receptors 1
and 2 in melanocytic nevi and malignant melanoma. Hum Pathol
36(6):676–685
55. Tellez CS et al (2007) Quantitative analysis of melanocytic tissue
array reveals inverse correlation between activator protein-2alpha
and protease-activated receptor-1 expression during melanoma
progression. J Invest Dermatol 127(2):387–393
56. Even-Ram S et al (1998) Thrombin receptor overexpression in
malignant and physiological invasion processes. Nat Med 4
(8):909–914
57. Kaushal V et al (2006) Thrombin receptor expression is
upregulated in prostate cancer. Prostate 66(3):273–282
58. Rudroff C et al (1998) Characterization of functional thrombin
receptors in human pancreatic tumor cells (MIA PACA-2).
Pancreas 16(2):189–194
59. Wojtukiewicz MZ et al (1995) Solid tumor cells express
functional “tethered ligand” thrombin receptor. Cancer Res 55
(3):698–704
60. Tellez C et al (2003) Loss of activator protein-2alpha results in
overexpression of protease-activated receptor-1 and correlates
with the malignant phenotype of human melanoma. J Biol Chem
278(47):46632–46642
61. Benveniste J et al (1979) Semi-synthesis and proposed structure
of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether
analog of lysophosphatidylcholine. C R Seances Acad Sci D 289
(14):1037–1040
62. Blank ML et al (1979) Antihypertensive activity of an alkyl ether
analog of phosphatidylcholine. Biochem Biophys Res Commun
90(4):1194–1200
63. Demopoulos CA, Pinckard RN, Hanahan DJ (1979) Platelet-
activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-
phosphorylcholine as the active component (a new class of lipid
chemical mediators). J Biol Chem 254(19):9355–9358
64. Benveniste J, Henson PM, Cochrane CG (1972) Leukocyte-
dependent histamine release from rabbit platelets. The role of
IgE, basophils, and a platelet-activating factor. J Exp Med 136
(6):1356–1377
65. Marathe GK et al (1999) Inflammatory platelet-activating factor-
like phospholipids in oxidized low density lipoproteins are
fragmented alkyl phosphatidylcholines. J Biol Chem 274
(40):28395–28404
66. Uemura Y, Lee TC, Snyder F (1991) A coenzyme A-independent
transacylase is linked to the formation of platelet-activating
factor (PAF) by generating the lyso-PAF intermediate in the
remodeling pathway. J Biol Chem 266(13):8268–8272
67. Montrucchio G, Alloatti G, Camussi G (2000) Role of platelet-
activating factor in cardiovascular pathophysiology. Physiol Rev
80(4):1669–1699
68. Blank ML et al (1988) Stimulation of the de novo pathway for
the biosynthesis of platelet-activating factor (PAF) via cytidylyl-
transferase activation in cells with minimal endogenous PAF
production. J Biol Chem 263(12):5656–5661
69. Shindou H et al (2007) A single enzyme catalyzes both platelet-
activating factor production and membrane biogenesis of inflam-
matory cells. Cloning and characterization of acetyl-CoA:
LYSO-PAF acetyltransferase. J Biol Chem 282(9):6532–6539
70. Bito H et al (1994) Cloning, expression and tissue distribution of
rat platelet-activating-factor-receptor cDNA. Eur J Biochem 221
(1):211–218
71. Nakamura M et al (1991) Molecular cloning and expression of
platelet-activating factor receptor from human leukocytes. J Biol
Chem 266(30):20400–20405
72. Ye RD et al (1991) Characterization of a human cDNA that
encodes a functional receptor for platelet activating factor.
Biochem Biophys Res Commun 180(1):105–111
73. Brizzi MF et al (1999) Thrombopoietin stimulates endothelial
cell motility and neoangiogenesis by a platelet-activating factor-
dependent mechanism. Circ Res 84(7):785–796
74. Camussi G et al (1995) Platelet-activating factor directly
stimulates in vitro migration of endothelial cells and promotes
in vivo angiogenesis by a heparin-dependent mechanism. J
Immunol 154(12):6492–6501
75. Camussi G et al (1997) Angiogenesis induced in vivo by
hepatocyte growth factor is mediated by platelet-activating factor
synthesis from macrophages. J Immunol 158(3):1302–1309
76. Montrucchio G et al (1994) Tumor necrosis factor alpha-induced
angiogenesis depends on in situ platelet-activating factor
biosynthesis. J Exp Med 180(1):377–382
77. Montrucchio G et al (1997) Nitric oxide mediates angiogenesis
induced in vivo by platelet-activating factor and tumor necrosis
factor-alpha. Am J Pathol 151(2):557–563
78. Montrucchio G et al (1998) Potential angiogenic role of platelet-
activating factor in human breast cancer. Am J Pathol 153
(5):1589–1596
79. Robert EG, Hunt JD (2001) Lipid messengers as targets for
antiangiogenic therapy. Curr Pharm Des 7(16):1615–1626
80. Bussolino F et al (1995) Platelet activating factor produced in
vitro by Kaposi's sarcoma cells induces and sustains in vivo
angiogenesis. J Clin Invest 96(2):940–952
81. Bussolati B et al (2000) PAF produced by human breast cancer
cells promotes migration and proliferation of tumor cells and
neo-angiogenesis. Am J Pathol 157(5):1713–1725
82. Axelrad TW et al (2004) Platelet-activating factor (PAF) induces
activation of matrix metalloproteinase 2 activity and vascular
endothelial cell invasion and migration. Faseb J 18(3):568–570
83. Deo DD et al (2002) Phosphorylation of STAT-3 in response to
basic fibroblast growth factor occurs through a mechanism
involving platelet-activating factor, JAK-2, and Src in human
umbilical vein endothelial cells. Evidence for a dual kinase
mechanism. J Biol Chem 277(24):21237–21245
84. Sirois MG, Edelman ER (1997) VEGF effect on vascular
permeability is mediated by synthesis of platelet-activating
factor. Am J Physiol 272(6 Pt 2):H2746–H2756
85. Rollin S et al (2004) VEGF-mediated endothelial P-selectin
translocation: role of VEGF receptors and endogenous PAF
synthesis. Blood 103(10):3789–3797
86. Maliba R et al (2006) Angiopoietins-1 and -2 are both capable of
mediating endothelial PAF synthesis: intracellular signalling
pathways. Cell Signal 18(11):1947–1957
87. Im SY et al (1996) Augmentation of tumor metastasis by
platelet-activating factor. Cancer Res 56(11):2662–2665
88. Sato S et al (1999) Accelerated proliferation of epidermal
keratinocytes by the transgenic expression of the platelet-
activating factor receptor. Arch Dermatol Res 291(11):614–621
89. Ishii S et al (1997) Bronchial hyperreactivity, increased endo-
toxin lethality and melanocytic tumorigenesis in transgenic mice
overexpressing platelet-activating factor receptor. Embo J 16
(1):133–142
90. Barber LA, Spandau DF, Rathman SC, Murphy RC, Johnson
CA, Kelley SW, Hurwitz SA, Travers JB (1998) Expression of
the platelet-activating factor receptor results in enhanced ultra-
110 V.O. Melnikova, et al.
violet B radiation-induced apoptosis in a human epidermal cell
line. J Biol Chem 273(30):18891–18897
91. Sheng Y, Birkle DL (1995) Release of platelet activating factor
(PAF) and eicosanoids in UVC-irradiated corneal stromal cells.
Curr Eye Res 14(5):341–347
92. Calignano A et al (1988) Isolation and identification of platelet-
activating factor in UV-irradiated guinea pig skin. J Pharmacol
Methods 19(1):89–91
93. Travers JB et al (1995) Identification of functional platelet-
activating factor receptors on human keratinocytes. J Invest
Dermatol 105(6):816–823
94. De Fabo EC et al (2004) Ultraviolet B but not ultraviolet A
radiation initiates melanoma. Cancer Res 64(18):6372–6376
95. Noonan FP et al (2001) Neonatal sunburn and melanoma in
mice. Nature 413(6853):271–272
96. Zhang Q et al (2005) Staphylococcal lipoteichoic acid inhibits
delayed-type hypersensitivity reactions via the platelet-activating
factor receptor. J Clin Invest 115(10):2855–2861
97. Biancone L et al (2003) Platelet-activating factor inactivation by
local expression of platelet-activating factor acetyl-hydrolase
modifies tumor vascularization and growth. Clin Cancer Res 9
(11):4214–4220
98. Fallani A et al (2006) Platelet-activating factor (PAF) is the effector
of IFN gamma-stimulated invasiveness and motility in a B16
melanoma line. Prostaglandins Other LipidMediat 81(3–4):171–177
99. Ko HM et al (2007) Critical role for matrix metalloproteinase-9 in
platelet-activating factor-induced experimental tumor metastasis.
Int J Cancer 120(6):1277–1283
100. Mannori G et al (2000) Interaction of tumor cells with vascular
endothelia: role of platelet-activating factor. Clin Exp Metastasis
18(1):89–96
101. Melnikova VO et al (2006) Platelet-activating factor mediates
MMP-2 expression and activation via phosphorylation of cAMP-
response element-binding protein and contributes to melanoma
metastasis. J Biol Chem 281(5):2911–2922
102. Deo DD, Bazan NG, Hunt JD (2004) Activation of platelet-
activating factor receptor-coupled G alpha q leads to stimulation
of Src and focal adhesion kinase via two separate pathways in
human umbilical vein endothelial cells. J Biol Chem 279
(5):3497–3508
PAR-1 and PAF in melanoma 111
